Lupin: Advanced markets focus - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

MidCapSelect
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Lupin: Advanced markets focus

Dec 23, 2003

Domestic pharma major, Lupin Ltd., announced its September quarter results recently. Strong revenue growth from the exports market has helped the company record an impressive 38% topline and 86% bottomline growth. For first half ended September '03, Lupin has recorded a 32% growth in net sales and 66% growth in net profits.

Results at a glance ...
(Rs m) 2QFY03 2QFY04 Change 1HFY03 1HFY04 Change
Net Sales 2,499 3,457 38.4% 4,627 6,094 31.7%
Other Income 34 83 144.8% 55 127 133.2%
Expenditure 1,966 2,679 36.3% 3,618 4,738 31.0%
Operating Profit (EBDIT) 532 778 46.1% 1,009 1,356 34.4%
Operating Profit Margin (%) 21.3% 22.5%   21.8% 22.2%  
Interest 152 150 -1.5% 323 309 -4.3%
Depreciation 61 71 15.4% 121 140 15.9%
Profit before Tax 353 641 81.5% 619 1033 66.8%
Tax 75 123 65.4% 138 235 70.4%
Profit after Tax/(Loss) 279 518 85.8% 481 798 65.8%
Net profit margin (%) 11.1% 15.0%   10.4% 13.1%  
No. of Shares (m) 40.1 40.1   40.1 40.1  
Diluted Earnings per share (Rs)* 27.8 51.6   24.0 39.8  
P/E Ratio (x)   14.3     18.5  
(* annualised)            

To Read the Full Story, Subscribe or Sign In
To Read the Full Story, Subscribe or Sign In


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Sep 21, 2020 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS